CHMP recommends extended use of Velcade (Janssen) for Multiple Myeloma
The CHMP has granted a positive opinion on two variations relating to the use of Velcade (bortezomib), from J&J Janssen Cilag. The first recommendation is for the use of Velcade as retreatment in adult Multiple Myeloma patients who have previously responded to treatment with the same medicine.
It also announced a positive opinion recommending the approval of Velcade as induction therapy in combination with dexamethasone (VD) or dexamethasone and thalidomide (VDT). This is for adult patients with previously untreated Multiple Myeloma who are eligible for high-dose chemotherapy with haematological stem cell transplantation.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.